Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D. P. Devanand

Showing results (201-210 of 215) with videos related to

Pageof 22
Sort By:
NEJM Evidence|August 28, 2023
Computerized Games versus Crosswords Training in Mild Cognitive ImpairmentD P Devanand, Terry E Goldberg, Min Qian, et al.
JAMA|December 17, 2025
Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical TrialD P Devanand, Thomas Wisniewski, Qolamreza Razlighi, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 4, 2012
Citalopram for agitation in Alzheimer's disease: design and methodsLea T Drye, Zahinoor Ismail, Anton P Porsteinsson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 31, 2021
Patterns of tau pathology identified with <sup>18</sup> F-MK-6240 PET imagingWilliam Charles Kreisl, Patrick J Lao, Aubrey Johnson, et al.
Alzheimer'S & Dementia (New York, N. Y.)|September 30, 2020
Agitation and impulsivity in mid and late life as possible risk markers for incident dementiaDaniel R Bateman, Sascha Gill, Sophie Hu, et al.
JAMA|February 20, 2014
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trialAnton P Porsteinsson, Lea T Drye, Bruce G Pollock, et al.
The American Journal of Psychiatry|April 2, 2016
Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD StudyAnne K Leonpacher, Matthew E Peters, Lea T Drye, et al.
Plos One|June 11, 2014
Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trialLea T Drye, David Spragg, D P Devanand, et al.
International Psychogeriatrics|August 26, 2015
Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trialPaul B Rosenberg, Lea T Drye, Anton P Porsteinsson, et al.
The American Journal of Psychiatry|January 16, 2016
Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical TrialLon S Schneider, Constantine Frangakis, Lea T Drye, et al.
Pageof 22

Showing results (201-210 of 215) with videos related to

Sort By:
Pageof 22
NEJM Evidence|August 28, 2023
Computerized Games versus Crosswords Training in Mild Cognitive ImpairmentD P Devanand, Terry E Goldberg, Min Qian, et al.
JAMA|December 17, 2025
Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical TrialD P Devanand, Thomas Wisniewski, Qolamreza Razlighi, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 4, 2012
Citalopram for agitation in Alzheimer's disease: design and methodsLea T Drye, Zahinoor Ismail, Anton P Porsteinsson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 31, 2021
Patterns of tau pathology identified with <sup>18</sup> F-MK-6240 PET imagingWilliam Charles Kreisl, Patrick J Lao, Aubrey Johnson, et al.
Alzheimer'S & Dementia (New York, N. Y.)|September 30, 2020
Agitation and impulsivity in mid and late life as possible risk markers for incident dementiaDaniel R Bateman, Sascha Gill, Sophie Hu, et al.
JAMA|February 20, 2014
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trialAnton P Porsteinsson, Lea T Drye, Bruce G Pollock, et al.
The American Journal of Psychiatry|April 2, 2016
Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD StudyAnne K Leonpacher, Matthew E Peters, Lea T Drye, et al.
Plos One|June 11, 2014
Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trialLea T Drye, David Spragg, D P Devanand, et al.
International Psychogeriatrics|August 26, 2015
Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trialPaul B Rosenberg, Lea T Drye, Anton P Porsteinsson, et al.
The American Journal of Psychiatry|January 16, 2016
Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical TrialLon S Schneider, Constantine Frangakis, Lea T Drye, et al.
Pageof 22